NCT06582797View on ClinicalTrials.gov

Analytical Treatment Interruption in a Patient With HIV Post Allogeneic Stem Cell Transplantation From a CCR5 delta32 Homozygous Donor

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2034

Study Completion Date

September 30, 2034

Conditions
HIV-1-infection
Interventions
OTHER

discontinuation of ART

patient will discontinue their standard of care HIV treatment with ART while being closely monitored

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Kansas Medical Center

OTHER